. Forex Trade Ideas - List of the Latest Trading Ideas

Oxford Biomedica lifts outlook as AstraZeneca ramps up vaccine output

Oxford Biomedica lifts outlook as AstraZeneca ramps up vaccine output

18 May 2021

AstraZeneca (NASDAQ:AZN) UP 0.62% AT 7944

Oxford Biomedica on Tuesday doubled the revenue expectation from its COVID-19 vaccine supply deal with AstraZeneca (NASDAQ:AZN) after the drug maker commissioned more batches from the company in the second half of 2021.

Shares of the cell therapy firm, which has an agreement to mass-produce AstraZeneca’s COVID-19 vaccine, rose 6.2% in early trading.

Oxford Biomedica raised its forecast for cumulative revenues from AstraZeneca by end-2021 to more than 100 million pounds ($141.82 million) from more than 50 million pounds earlier. The company did not provide any other details on its deal.

Liberum analysts said the increased supply deal was a “huge endorsement” of Oxford Biomedica’s capabilities, and that a further extension from AstraZeneca feels “increasingly likely”.

AstraZeneca has had a bruising start to the year as it struggled with vaccine production and faced a legal battle after cutting deliveries to Europe.

Oxford Biomedica was spun off in 1995 from the University of Oxford, which developed the COVID-19 vaccine before licensing it to AstraZeneca in April 2020.

On technical fronts AstraZeneca (NASDAQ:AZN) RSI stood at 66.31 and currently stock is trading above all Moving Average. So, BUY position can be taken with following target and stoploss:

TRADE SIGNAL – : AstraZeneca (NASDAQ:AZN) – BUY: 7943, TARGET: 8022, STOP LOSS : 7835